Home > Neurology > ECTRIMS 2019 > Monitoring and Treatment of Progressive MS > Late-breaking: Myelin-peptide coupled red blood cells

Late-breaking: Myelin-peptide coupled red blood cells

Presented By
Prof. Andreas Lutterotti, University of Zurich, Switzerland
Conference
ECTRIMS 2019
Trial
Phase 1, ETIMS-red
Induction of antigen-specific immune tolerance is a promising therapeutic approach in autoimmune diseases. Peptide-coupled cell tolerance is effective in several animal models of autoimmune disease, allergies and transplantation. Prof. Andreas Lutterotti (University of Zurich, Switzerland) and colleagues developed a therapeutic regimen employing autologous blood cells, chemically coupled with 7 myelin peptides, to induce antigen-specific tolerance in MS patients [1]. After a successful trial with myelin peptide-coupled peripheral blood mononuclear cells (PBMCs) in MS patients, the researchers optimised the approach using red blood cells (RBCs) as tolerogenic carriers (see Figure) [2]. ETIMSred is the first-in-human phase 1b trial, to test the safety and tolerability of increasing doses of autologous peptide-coupled RBCs. Ten relapsing-remitting MS patients (mean age 38.5; 70% female) were treated with increasing doses of peptide-coupled RBCs.


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on